Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
shop dildos - is great for every girl.
Popular Articles

Report Highlights Importance Of GPs, Australian Medical Association
A new Australian Institute of Health and Welfare/University of Sydney report on General Practice highlights the critical role GPs play in keeping the Australian community healthy, AMA Federal President, Dr Andrew Pesce, said today.
drugs without prescription
Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, announced final data from three separate Phase II trials involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) small molecule drug. The final data was recently presented at the American Diabetes Association"s "69th Scientific Sessions" in New Orleans, LA on June 7, 2009 and the International Symposium on Atherosclerosis (ISA) in Boston, MA on June 15, 2009.
News of the day
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data In Patients With Schizophrenia
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from the first phase 3 clinical trial for lurasidone, which is under clinical development globally, for the treatment of patients with schizophrenia. In this six-week, double-blind, placebo-controlled trial, lurasidone 80 mg/day was significantly more effective than placebo for the treatment of acute schizophrenia. In addition, lurasidone was well-tolerated and had a relatively low discontinuation rate. The findings were presented at the 162nd Annual Meeting of the American Psychiatric Association in San Francisco, held on May 16-21.
Health Insurance

Obama Nominates Human Genome Veteran To Lead NIH

Dr. Francis S. Collins, the Yale-educated, guitar-strumming physician and geneticist who led the Human Genome Project, was nominated Wednesday to head the National Institutes of Health, the New York Times reports. "Dr. Collins"s selection, which had been rumored for weeks, was praised by top scientists and research advocacy organizations for whom the health institute is a crucial patron," the Times reports. He is expected to sail through Senate confirmation. Collins has, however, earned skepticism in addition to praise. Some in the scientific community object to his religiousness and see his work as a kind of evangelism: "He wrote a book called "The Language of God," and he has given many talks and interviews in which he described his conversion to Christianity as a 27-year-old medical student." Another criticism is that, while managing the Human Genome Project, he over-inflated expectations, and then delivered little return - in terms of practical medical breakthroughs - on the massive investment when unexpected "scientific hurdles" emerged (Harris, 7/8). However, science continues to pursue personalized medicine based on genomics. "[T]he true power of genetics, he told a meeting of scientists in Washington last month, has yet to be realized as researchers eventually learn enough to provide customized predictions of which diseases really threaten an individual, and personalized care to respond," The Associated Press/Wall Street Journal report. "His groundbreaking work has changed the very ways we consider our health and examine disease," President Obama said when announcing the nomination (7/8). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009